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Introduction 
Aromatase inhibitors (AIs) have been used as the first choice of 
adjuvant endocrine therapy for postmenopausal women over 
the last 15 years since they are more effective than tamoxifen for 
postmenopausal breast cancer, and AI prescriptions account for 
64% of endocrine therapy among women with invasive breast 
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Purpose: Aromatase inhibitors (AIs) are widely prescribed for postmenopausal women with breast 
cancer and are known to cause musculoskeletal pain. This study aimed to identify factors associated 
with AI continuation intention among breast cancer survivors (BCS). 
Methods: A cross-sectional survey was conducted on 123 BCS (stages I–III), who had been taking 
AIs for at least 6 weeks. Participants were recruited from a cancer center in Goyang, Korea, from 
September to November 2019. Descriptive statistics, Welch analysis of variance, Pearson correlation 
coefficients, and simple linear regression were used for the analysis. 
Results: Beliefs about endocrine therapy was a significant predictor of AI continuation intention 
(β=.66, p<.001). The majority of participants (87.0%) reported experiencing musculoskeletal pain 
since taking AIs and the score for the worst pain severity within 24 hours was 5.08±2.80 out of 10. 
Musculoskeletal pain, however, was not associated with AI continuation intention. Fear of cancer re-
currence (FCR) was clinically significant (≥13) for 74.0% of the respondents (mean, 17.62±7.14). 
Musculoskeletal pain severity and pain interference were significantly associated with FCR (r=.21, 
p<.05; r=.35, p<.01, respectively). Pain interference was significantly associated with beliefs about 
endocrine therapy (r=–.18, p<.05). 
Conclusion: AI continuation intention can be modified by reinforcing patients’ beliefs about endo-
crine therapy. Musculoskeletal pain may have a negative effect on beliefs about endocrine therapy 
and increase FCR among BCS. Thus, awareness of musculoskeletal pain during AI therapy should 
be raised and further research is required to develop multidisciplinary pain management strategies 
and clinical guidelines to reinforce beliefs about endocrine therapy. 
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cancer [1]. After menopause, estrogen production by the ova-
ries terminates and estrogen is synthesized by aromatase in pe-
ripheral tissues. Hence, suppression of estrogen is more effec-
tively achieved by using AIs, as they primarily block most of the 
production of estrogen. 
To take full advantage of endocrine therapy, it is important to 
take the medication regularly throughout the recommended pe-
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riod [2]. However, issues with endocrine therapy adherence re-
main an unsolved problem. Breast cancer survivors (BCS) make 
a decision to continue or discontinue AI therapy every day and 
can reverse their decision at any time. Beryl and colleagues ob-
served adjuvant endocrine therapy adherence among 35 BCS 
for 280 ± 96 days. None of the patients started and continued 
medication based on a concrete decision, and only four patients 
were still taking the medication, without any reservations, at the 
final interview. Moreover, 68% of them stated that their decision 
could change at any time regardless of whether they were taking 
the medication [3]. This implies that assessing AI continuation 
intention is as important for maximizing AI adherence as assess-
ing adherence itself. AI continuation intention refers to an inten-
tion to continue AI therapy and is conceptually mirrored by dis-
continuation intention, such as “uncertainty about persisting” 
[4] or “thought about stopping endocrine therapy” [5]. Since 
intention to take medication is a known predictor of medication 
adherence [6], it is expected that AI discontinuation can be pre-
vented or altered by modifying or reinforcing intention during 
the decision-making process. 
Newly developed or aggravated musculoskeletal pain, a major ad-
verse effect of AI, is frequently reported as a cause of patient-driven 
AI discontinuation, unlike tamoxifen [7,8]. According to Lombard 
et al. [8], 82% of BCS taking AI as adjuvant endocrine therapy re-
ported AI-associated musculoskeletal pain and 68% of nonadherent 
participants discontinued AI due to musculoskeletal pain. In Korea, 
a retrospective medical record study reported AI-associated arthral-
gia in 23% of BCS [9]. However, its relation to patient-driven dis-
continuation was not evaluated. Studies on AI adherence and AI-as-
sociated musculoskeletal pain have mainly been conducted in the 
United States, Europe, and Australia. Since musculoskeletal pain 
has been blamed for AI discontinuation, international research 
Summary statement
• What is already known about this topic?
Newly developed or aggravated musculoskeletal pain since taking aromatase inhibitors (AIs) is known to be the main cause of 
nonadherence of AIs in breast cancer survivors.
• What this paper adds
While musculoskeletal pain was common and had negative effects on daily life, beliefs about endocrine therapy, and increased fear of 
cancer recurrence, it did not affect AI continuation intention. Beliefs about endocrine therapy was the only significant predictor of AI 
continuation intention.
• Implications for practice, education, and/or policy
Nurses should regularly assess musculoskeletal pain and beliefs about endocrine therapy in patients taking AI and provide emo-
tional support in addition to pain management.
assessing the prevalence and risk factors of musculoskeletal pain 
has been actively conducted and is expanding to include the de-
velopment of interventions to alleviate pain and improve the AI 
continuation rate [10]. Nevertheless, research on the self-re-
ported incidence of musculoskeletal pain and its relation to AI 
continuation intention has not yet been conducted in Korea. 
In addition to adverse effects, previous studies have found 
that endocrine therapy continuation was also associated with 
fear of cancer recurrence (FCR) [4] and beliefs about endocrine 
therapy [4,11,12]. Pain is known to amplify FCR in BCS [13] 
and a study conducted with breast cancer patients undergoing 
AI therapy showed that FCR was higher in patients who experi-
enced musculoskeletal pain than in those who did not [14]. 
However, the relationship of pain to AI continuation was not 
evaluated. FCR plays a role in maintaining endocrine therapy 
among BCS with weak beliefs about endocrine therapy [4]. Be-
liefs about endocrine therapy has been reported to be the most 
powerful and important factor affecting the continuation of en-
docrine therapy [12] but can be negated by the adverse effects 
of endocrine therapy [4,11,15]. However, previous studies re-
garding beliefs about endocrine therapy were predominantly 
conducted among BCS taking tamoxifen and included only a 
small proportion of patients taking AIs. Thus, the roles of beliefs 
about endocrine therapy and FCR among patients receiving AI 
therapy have yet to be elucidated. 
Therefore, this study aimed to identify (1) whether AI con-
tinuation intention differed according to whether patients expe-
rienced newly developed or aggravated musculoskeletal pain 
since taking AIs; (2) the relationships among the main variables; 
and (3) factors associated with AI continuation intention. 
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Methods 
Ethics statement: This study was approved by the Institutional 
Review Board of Korea National Cancer Center (No. NCC2019-
0235). Informed consent was obtained from the participants.
Design and participants 
This cross-sectional correlational research was conducted at a 
cancer center located in Goyang, Gyeonggi Province, Korea, 
from September 16 to November 14, 2019. The participants 
were recruited via convenience sampling among patients visiting 
the outpatient clinic of the center for breast cancer. Based on the 
findings of a previous study that AI-associated musculoskeletal 
pain started after 6 weeks on average [16], the inclusion criteria 
were as follows: (1) stage I–III breast cancer; (2) completed 
surgery, adjuvant chemotherapy, and radiation therapy; and (3) 
at least 6 weeks on AI medication [16]. BCS who were treated 
for other cancers and metastatic breast cancer (stage IV) were 
excluded to rule out other causes of musculoskeletal pain. The 
sample size needed for multiple linear regression, calculated us-
ing G*Power 3.1.9.2 (α error probability = .05, statistical pow-
er = 90%, effect size = .15 [17], and four predictors: pain severity 
[7,11], pain interference [11,18], FCR [4], and beliefs about 
endocrine therapy [4,12]), based on the literature was at least 
108. Considering a 20% dropout rate, questionnaires were dis-
tributed to 129 BCS and 123 completed questionnaires without 
missing information were included in the analyses. 
Assessment tools 
A self-reported questionnaire including AI continuation inten-
tion, musculoskeletal pain, FCR, beliefs about endocrine thera-
py, and general characteristics was used. Permission to use each 
assessment tool was obtained from both the developers and the 
authors of adapted/translated versions by e-mail. 
Aromatase inhibitor continuation intention 
A five-item measure of intentions to take cardiac medication [6] 
was modified to evaluate AI continuation intention, with per-
mission from the developer. For example, the item “I plan to 
take regular medication in the future” was modified to “I plan to 
continue endocrine therapy in the future.” The five items evalu-
ated intentional plan to take medication, intention to make an 
effort to take the medication, intention to persist and adhere 
with the medication, and the perceived possibility of taking the 
medication. Each item is rated on a 5-point scale (1–5), with a 
possible total score ranging from 5 to 25, and higher scores indi-
cate greater intention. Cronbach’s α was .88 at the time of devel-
opment [6] and .98 in this study. 
Musculoskeletal pain 
Musculoskeletal pain was evaluated with the Korean version 
[19] of the Brief Pain Inventory-Short Form (BPI-SF) [20]. 
Pain severity (four items) and pain interference (seven items) 
are rated on an 11-point scale (0–10), with a higher score indi-
cating more severe pain and pain interference. Cronbach’s α was 
.80 to .92 at the time of development [20] and was .89 for pain 
severity and .94 for pain interference in this study. 
Fear of cancer recurrence 
FCR was evaluated with the Fear of Cancer Recurrence Inven-
tory-Short Form (FCRI-SF) [21] Korean version [22], which 
consists of nine items rated on a 5-point scale (0–4), with a pos-
sible total score range of 0 to 36 and a higher score indicating a 
greater FCR. A cutoff score of 13 or higher is considered clini-
cally significant [21]. Cronbach’s α was .89 at the time of devel-
opment [23], .77 in a study with a Korean population [22], and 
.83 in this study. 
Beliefs about endocrine therapy 
The 22-item Endocrine Therapy Beliefs Scale [24], which was 
developed in Korean, was used to measure the cognitive re-
sponse to endocrine therapy. It consists of four subcategories: 
perceived control (11 items), perceived concerns (four items), 
perceived benefits and trust (five items), and perceived logic 
(two items). Each item is rated on a 4-point scale (1–4), with a 
possible total score range of 22 to 88, and a higher score indi-
cates a stronger beliefs about endocrine therapy. Cronbach’s α 
was .91 at the time of development [24] and .90 in this study. 
General characteristics 
A short questionnaire was developed to collect information 
about demographic and disease-related characteristics relevant 
for AI adherence [4,12]. General characteristics included age, 
cancer stage, breast cancer treatment, time since menopause, 
body mass index, and history of musculoskeletal disease.  
Data analyses 
The data were analyzed using IBM SPSS ver. 25.0 (IBM Corp., 
Armonk, NY, USA). Differences in AI continuation intention 
according to musculoskeletal pain were examined using Welch 
analysis of variance. Correlations among variables were examined 
using Pearson correlation coefficients, and regression analysis was 
done to identify factors influencing AI continuation intention. 
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The demographic and clinical characteristics of the 123 respon-
dents are shown in Table 1. The mean age of the participants 
was 58.06 ± 7.41 years, and they ranged in age from 30 to 80 
years old. Among AI medications, letrozole (n = 89, 72.4%) was 
prescribed twice as often as anastrozole (n = 34, 27.6%), reflect-
ing clinical practice. The mean duration of AI medication was 
2.55 ± 1.54 years and two participants had been taking AI for 
longer than 5 years. More than one-third of participants (n = 44, 
35.8%) had been diagnosed with musculoskeletal diseases and 
27 of them (61.4%) reported that the diagnosis was made after 
initiating AI medication. 
Aromatase inhibitor continuation intention 
The mean score of AI continuation intention was 22.28 ± 4.34, 
which is interpreted as high (Table 2). 
Musculoskeletal pain, fear of cancer recurrence, and beliefs 
about endocrine therapy 
In total, 107 participants (87.0%) reported that they experi-
enced newly developed or aggravated musculoskeletal pain after 
the commencement of AI. The score for the worst pain within 
24 hours was 5.08 ± 2.80, indicating moderate pain requiring ac-
tive pain management, and the mean score for the worst, the 
Table 1. General characteristics of the participants (N=123)
Variable Categories Mean±SD (range) n (%)




Cancer stage Stage I 55 (44.7)
Stage II 41 (33.3)
Stage III 27 (22.0)
Chemotherapy Yes 68 (55.3)
No 55 (44.7)
Radiation therapy Yes 120 (97.6)
No 3 (2.4)
Type of AI Letrozole 89 (72.4)
Anastrozole 34 (27.6)





Previous use of tamoxifen No 107 (87.0)
Yes 16 (13.0)




Body mass index (kg/m2) 23.49±3.10
Normal (<23) 63 (51.2)
Overweight (23–24.9) 22 (17.9)
Obese (≥25) 38 (30.9)
MSD No 79 (64.2)
Yes 44 (35.8)
 Diagnostic point of MSD Before AI 17 (38.6)
After AI 27 (61.4)
AI: Aromatase inhibitor; MSD: musculoskeletal disease.
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least, the average, and present pain was 3.29 ± 2.12, indicating 
mild pain. Musculoskeletal pain was most commonly reported 
as interfering with mood (4.39 ± 2.90), sleep (4.26 ± 3.32), and 
general activities (4.11 ± 3.28) (Table 2). 
The mean score for FCR was 17.62 ± 7.14, and 74.0% of par-
ticipants had clinically significant FCR ( ≥ 13). The mean score 
for beliefs about endocrine therapy was 67.54 ± 9.49, which is 
interpreted as high (Table 2). 
Aromatase inhibitor continuation intention according to 
musculoskeletal pain 
To evaluate the difference in AI continuation intention according to 
pain severity, the mean scores for the worst, the least, the average, 
and present pain were classified into three groups; none (score of 0), 
mild (1–3), and moderate (4–7). There was no mean score greater 
than 7. The scores for the worst pain within 24 hours were classified 
into four groups—none (score of 0), mild (1–3), moderate (4–7), 
and severe (8–10) [25]—because AI continuation intention may 
be most strongly affected by the worst pain, and the use of a single 
item for the worst pain severity is also supported by the BPI user 
guide [26]. The analysis showed that there were no significant dif-
ferences in AI continuation intention between the groups (Table 3). 
Relationships among aromatase inhibitor continuation 
intention, musculoskeletal pain, fear of cancer recurrence, 
and beliefs about endocrine therapy 
The correlations among variables are shown in Table 4. A mod-
erate correlation was found between AI continuation intention 
and beliefs about endocrine therapy (r = .66, p< .01). FCR had a 
weak relationship with both pain severity (r = .21, p< .05) and 
pain interference (r = .35, p< .01). Beliefs about endocrine ther-
apy had a weak relationship with pain interference (r = – .18, 
p< .05)  
Beliefs about endocrine therapy as a factor influencing 
aromatase inhibitor continuation intention 
Beliefs about endocrine therapy was the only factor that influ-
enced AI continuation intention. The regression model was sta-
tistically significant (F = 95.66, p< .001), explaining 44% of AI 
continuation intention (Table 5). The Durbin-Watson value 
was 2.027, implying independence of the residual without auto-
correlation. The normality of residuals was examined using a 
histogram and a normal probability plot. 
Discussion 
Beliefs about endocrine therapy was the only factor with a statis-
Table 2. Aromatase inhibitor continuation intention, musculoskeletal pain, fear of cancer recurrence, and beliefs about endocrine therapy 
(N=123)
Variable Possible score Mean±SD n (%) Range
AI continuation intention 5–25 22.28±4.34 123 (100) 5–25
Musculoskeletal pain
Pain severity† 0.25–10 3.29±2.12 107 (87.0) 0.50–7.00
  Worst pain during the last 24 hours 1–10 5.08±2.80 1–10
  Average pain 0–10 3.96±2.36 1–8
  Least pain during the last 24 hours 0–10 2.17±1.91 0–6
  Present pain 0–10 1.93±2.57 0–9
Pain interference‡ 0.14–10 3.82±2.66 107 (87.0) 0.14–9.29
 Mood 0–10 4.39±2.90 0–10
 Sleep 0–10 4.26±3.32 0–10
 General activities 0–10 4.11±3.28 0–10
 Usual work 0–10 4.06±3.21 0–10
 Enjoyment of life 0–10 3.81±3.29 0–10
 Walking ability 0–10 3.38±3.15 0–10
 Interpersonal relationships 0–10 2.75±3.24 0–10
Fear of cancer recurrence 0–36 17.62±7.14 123 (100) 4–35
 Clinical level (≥13) 13–36 91 (74.0)
 Nonclinical level 0–12 32 (26.0)
Beliefs about endocrine therapy 22–88 67.54±9.49 38–88
†Pain severity=(worst+least+average+present pain)/4; ‡Pain interference=sum of seven-item scores/7.
AI: Aromatase inhibitor
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tically significant effect on AI continuation intention in this study 
of BCS who reported newly developed or aggravated musculo-
skeletal pain since taking AI. This result is comparable to results 
of previous studies, conducted among BCS either taking AI or 
tamoxifen, according to which beliefs about endocrine therapy 
was the most powerful factor affecting medication adherence 
[4,12] and was associated with intention to take endocrine thera-
py [27]. It is also consistent with the finding of a qualitative study 
that breast cancer patients continuously reassess the necessity of 
endocrine therapy, its risks, and other options during endocrine 
therapy, and if they become doubtful about it efficacy they are 
likely to make a decision to stop taking the medication [3]. The 
findings of this study thus underscore the need to develop inter-
ventions for maintaining and reinforcing beliefs about endocrine 
therapy during the period which it is prescribed, which is usually 
5 years. Further studies that can identify intervention time 
points, methods, and screening techniques for vulnerable popu-
lations will also be beneficial. 
The majority of the participants (87%) experienced newly 
developed or aggravated musculoskeletal pain after taking AI, 
which is a higher proportion than found in a previous study 
(73.7%) [28], and the worst pain severity within 24 hours was 
5.08 ± 2.80, suggesting the need for active pain control manage-
ment. Musculoskeletal pain severity showed a significant posi-
tive correlation with pain interference and FCR. Thus, a multi-
disciplinary approach is needed for pain management for newly 
developed or aggravated musculoskeletal pain after taking AI. 
Nevertheless, no significant relationship was found between 
musculoskeletal pain and AI continuation intention, unlike pre-
vious studies conducted in other countries [7,8,18]. In a study 
done in the USA, musculoskeletal symptoms were highly asso-
ciated with early discontinuation of AI (hazard ratio, 4.39; 95% 
CI, 2.4–8.02; p< .0001) [18] and in a study done in Australia, 
68% of BCS reported AI discontinuation due to AI-related mus-
culoskeletal pain [8]. In addition, a prior study done in the USA 
reported that a moderate or higher worst pain score ( > 4 on the 
BPI) was a predictor of premature discontinuation of AIs [7]. 
The reason for this discrepancy may be related to the high levels 
of AI continuation intention in the present study, the difficulty 
in making direct comparisons due to prior studies’ focus on 
continuation behaviors rather than intention, and the discrepan-
cy between intention and behavior. In a previous study conduct-
ed to identify predictors of thoughts about stopping endocrine 
treatment (either tamoxifen or AIs), 30% of the participants re-
Table 3. Differences in aromatase inhibitor continuation intention according to pain severity (N=123)
Pain severity Categories (score) n (%) Mean±SD F p
Total mean† None (0) 19 (15.4) 21.95±5.46 0.37 .689
Mild (1–3) 55 (44.7) 22.65±3.62
Moderate (4–7) 49 (39.8) 21.98±4.67
Worst pain severity Not at all (0) 17 (13.8) 22.41±5.32 1.04 .380
Mild (1–3) 30 (24.4) 23.30±3.28
Moderate (4–7) 49 (39.8) 22.14±3.99
Severe (8–10) 27 (22.0) 21.30±4.34
Number of severe pain category (score≥7) in total mean pain is zero.
†Total mean=(worst+least+average+present pain)/4.
Table 4. Correlations among study variables (N=123)
Variable Pain severity Pain interference Fear of cancer recurrence Beliefs about endocrine therapy
Pain severity 1
Pain interference .48** 1
Fear of cancer recurrence .21* .35** 1
Beliefs about endocrine therapy –.05 –.18* .09 1
AI continuation intention –.03 –.04 .01 .66**
AI: Aromatase inhibitor.
*p<.05, **p<.01.




B SE β t p
(constant) 1.73 2.12 .82 .42
Beliefs about endocrine therapy .31 .03 .66 9.78 < .001
F (p)=95.66 (< .001), R2 = .437, adjusted R2 = .442
B: Unstandardized; β: standardized coefficient.
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ported that they considered discontinuing endocrine therapy in 
addition to the 36% of participants who had already stopped en-
docrine therapy, and symptom severity was most strongly asso-
ciated with these thoughts [5]. A direct comparison is difficult 
because different measurement tools were used and 39% of par-
ticipants in the previous study were premenopausal women, 
which may affect symptom severity. However, the intention to 
continue AIs among those who either discontinued or consid-
ered stopping endocrine therapy in that study [5] was presum-
ably lower than this study’s level of 22.28 ± 4.34. Although pre-
vious studies [7,18] of AI (non)adherence focused on behavior 
rather than intention, an accurate identification of BCS who are 
indecisive about AI continuation would be helpful for prevent-
ing premature discontinuation and encouraging BCS to com-
plete the therapy during the recommended period. Thus, fur-
ther research should develop valid tools evaluating intention to 
continue endocrine therapy and seek to identify vulnerable 
populations. In addition, the discrepancy between intention and 
behavior may be relevant. In this study, AI continuation inten-
tion was measured instead of adherence (i.e., a behavioral vari-
able), considering the lack of reliability and evidence regarding 
self-reported measures of medication adherence [29]. Although 
intention to take medication is a predictor of medication adher-
ence [6], actual behavior can differ. Thus, other factors should 
be considered when using intention as a predictor of behavior, 
and further studies with a longitudinal design are required to 
evaluate the predictive power of intention on adherence in the 
context of endocrine therapy with AI. 
A significant issue is that 74.0% of participants reported clini-
cally significant FCR ( ≥ 13) and the average FCR score 
(17.62 ± 7.14) was also higher than the result of a previous study 
conducted among patients taking AIs (14.8) [14]. Despite the 
moderate pain severity, the finding of a high degree of FCR in 
this study is worthy of notice. FCR also had a weak relationship 
with pain severity and pain interference. This result implies that 
strategies to deal with FCR should be included in developing 
multidisciplinary nursing interventions for BCS. Although FCR 
in this study was higher than found in a previous study, it had no 
effect on AI continuation intention, which may be related to the 
high level of beliefs about endocrine therapy found in this study. 
Since it has been noted that FCR plays a role in endocrine thera-
py continuation among BCS with low levels of beliefs about en-
docrine therapy [4], further research should explore this inter-
play. 
This cross-sectional study has several limitations. First, gener-
alizability is limited as participants were recruited via conve-
nience sampling from a single institution. Second, the discrep-
ancy between AI continuation intention and AI adherence be-
havior was not evaluated. Although intentions explain behaviors 
to some extent, the predictability of actual AI continuation was 
not evaluated, as AI-taking behavior was not the focus of this 
study. Third, measurement issues may need to be considered, as 
the BPI-SF was not specifically developed to assess AI-related 
musculoskeletal pain and BCS often experience upper body dis-
comfort and neuropathy after surgery, chemotherapy, and radia-
tion therapy. While the researcher emphasized the aim of assess-
ing newly developed or aggravated musculoskeletal pain after 
taking AI to improve the accuracy of the assessments, it is possi-
ble that the measurements may have only partially captured the 
actual pain that BCS experienced. 
Despite the limitations, this study is meaningful from two 
perspectives. The findings present the current status of AI-relat-
ed musculoskeletal pain, as self-reported by Korean BCS; to our 
knowledge, this is a novel contribution. Second, the evaluation 
of the relationship of musculoskeletal pain to AI continuation 
intention in a Korean population is also significant, since data 
indicating low AI adherence have been published from other 
countries, but the relevance of those findings to nursing practice 
in Korea has not been clear. This study’s finding can improve 
clinicians’ understanding of musculoskeletal pain during AI 
therapy and can be used to develop nursing interventions for 
musculoskeletal pain management and improving endocrine 
therapy continuation intention. 
In conclusion, beliefs about endocrine therapy was a signifi-
cant predictor of AI continuation intention, whereas musculo-
skeletal pain during AI therapy did not negatively affect AI con-
tinuation intention. The incidence of the pain and the pain se-
verity, however, was high enough to require active pain manage-
ment in this sample of BCS. Pain also had a moderate positive 
relationship with pain interference, and had a positive, albeit 
weak, relationship with FCR. Thus, there is a need to raise 
awareness and educate patients about the incidence and the se-
verity of AI-related musculoskeletal pain and its impact, through 
educational programs or by distributing educational resources. 
Nursing interventions that support and reinforce beliefs about 
endocrine therapy are needed, and incorporating multidisci-
plinary pain management may be beneficial. 
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